Results from a phase 1/2, first-in-human, dose escalation and dose expansion study of an investigational anti-ADAM9 antibody-drug conjugate IMGC936 in patients with advanced solid tumors

被引：0

作者：

Subbiah, V. ^{[1
]}

Falchook, G. ^{[2
]}

Davis, A. A. ^{[3
]}

Wang, J. S. ^{[4
]}

de Miguel, M. ^{[5
]}

Santoro, A. ^{[6
]}

Maur, M. ^{[7
]}

Aljumaily, R. ^{[8
]}

Boni, V. ^{[9
]}

de Speville, B. Doger ^{[10
]}

Sun, Y. ^{[11
]}

Du, Y. ^{[12
]}

Lakshmikanthan, S. ^{[13
]}

Bedse, G. ^{[14
]}

Ward, A. ^{[15
]}

Zweidler-McKay, P. ^{[11
]}

Gandhi, L. ^{[16
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX USA

[2] HealthONE, Sarah Cannon Res Inst, Dept Drug Dev, Denver, CO USA

[3] Washington Univ St Louis, Div Oncol, St Louis, MO USA

[4] Florida Canc Specialists Sarah Cannon Res Inst, Drug Dev Unit, Sarasota, FL USA

[5] START Madrid CIOCC HM Sanchinarro, Early Phase Clin Trial Program, Madrid, Spain

[6] Humanitas Univ, Dept Biomed Sci, Humanitas Canc Ctr, IRCCS Humanitas Res Hosp, Milan, Italy

[7] Azienda Osped Univ Policlin Modena, Div Oncol, Modena, Italy

[8] Univ Oklahoma, Sect Hematol Oncol, Stephenson Canc Ctr, Hlth Sci Ctr, Oklahoma City, OK USA

[9] NEXT Madrid Univ Hosp Quironsalud, Oncol Early Drug Dev Unit, Madrid, Spain

[10] START Madrid FJD Hosp Univ Fdn Jimenez Diaz, Early Phase Clin Trials Unit, Madrid, Spain

[11] ImmunoGen Inc, Clin Dev, Waltham, MA USA

[12] ImmunoGen Inc, Biostat, Waltham, MA USA

[13] ImmunoGen Inc, Translat Med, Waltham, MA USA

[14] ImmunoGen Inc, Clin Pharmacol, Waltham, MA USA

[15] MacroGenics Inc, Clin Dev, Rockville, MD USA

[16] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

来源：

EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷

关键词：

D O I：

10.1016/j.ejca.2024.114703

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PB170

引用

页码：S72 / S73

页数：2

共 50 条

[1] First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
Hassan, Raffit
Blumenschein, George R., Jr.
Moore, Kathleen N.
Santin, Alessandro D.
Kindler, Hedy L.
Nemunaitis, John J.
Seward, Shelly M.
Thomas, Anish
Kim, Stella K.
Rajagopalan, Prabhu
Walter, Annette O.
Laurent, Dirk
Childs, Barrett H.
Sarapa, Nenad
Elbi, Cem
Bendell, Johanna C.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) : 1824 - +
[2] First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
Strickler, John H.
Weekes, Colin D.
Nemunaitis, John
Ramanathan, Ramesh K.
Heist, Rebecca S.
Morgensztern, Daniel
Angevin, Eric
Bauer, Todd M.
Yue, Huibin
Motwani, Monica
Parikh, Apurvasena
Reilly, Edward B.
Afar, Daniel
Naumovski, Louie
Kelly, Karen
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (33) : 3298 - +
[3] A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
Charlotte Lemech
Natasha Woodward
Nancy Chan
Joanne Mortimer
Louie Naumovski
Silpa Nuthalapati
Bo Tong
Fang Jiang
Peter Ansell
Christine K. Ratajczak
Jasgit Sachdev
Investigational New Drugs, 2020, 38 : 1815 - 1825
[4] A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
Lemech, Charlotte
Woodward, Natasha
Chan, Nancy
Mortimer, Joanne
Naumovski, Louie
Nuthalapati, Silpa
Tong, Bo
Jiang, Fang
Ansell, Peter
Ratajczak, Christine K.
Sachdev, Jasgit
INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1815 - 1825
[5] Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met-targeting antibody-drug conjugate, in advanced solid tumors
Sharma, Manish
Kuboki, Yasutoshi
Camidge, D. Ross
Perets, Ruth
Sommerhalder, David
Yamamoto, Noboru
Bar, Jair
Parikh, Apurvasena
Li, Rui
Thiele, Gladys Morrison
Aristide, Martha Raluca Neagu
Freise, Kevin Jay
Powderly, John D.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[6] First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors
Angevin, E.
Kelly, K.
Heist, R.
Morgensztern, D.
Weekes, C.
Bauer, T. M.
Ramanathan, R. K.
Nemunaitis, J.
Fan, X.
Olyaie, O.
Parikh, A.
Reilly, E.
Afar, D.
Naumovski, L.
Strickler, J.
ANNALS OF ONCOLOGY, 2016, 27
[7] First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors
Wang, Yakun
Gong, Jifang
Lin, Rongbo
Zhao, Shen
Wang, Jufeng
Wang, Qianli
Zhang, Yanqiao
Su, Dan
Zhang, Jingdong
Dong, Qian
Lin, Ling
Tian, Wen
Chen, Ying
Yang, Yang
Zhang, Xueyuan
Wan, Xuechao
Gao, Jinfeng
An, Na
Jansen, Valerie Malyvanh
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[8] Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors.
Powderly, John D.
Jang, Sekwon
Lohr, Joanna
Spira, Alexander, I
Bohac, Gerry C.
Sharma, Manish
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors (vol 36, pg 3298, 2018)
Strickler, J. H.
Weekes, C. D.
Nemunaitis, J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (03) : 261 - 261
[10] A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
Naing, Aung
Gainor, Justin F.
Gelderblom, Hans
Forde, Patrick M.
Butler, Marcus O.
Lin, Chia-Chi
Sharma, Sunil
de Olza, Maria Ochoa
Varga, Andrea
Taylor, Matthew
Schellens, Jan H. M.
Wu, Hongqian
Sun, Haiying
Silva, Antonio P.
Faris, Jason
Mataraza, Jennifer
Cameron, Scott
Bauer, Todd M.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)

← 1 2 3 4 5 →